128 related articles for article (PubMed ID: 23413899)
1. Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures?
Barbuto JA
Immunotherapy; 2013 Feb; 5(2):105-7. PubMed ID: 23413899
[No Abstract] [Full Text] [Related]
2. Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.
Bohnenkamp HR; Burchell JM; Taylor-Papadimitriou J; Noll T
J Immunol Methods; 2004 Nov; 294(1-2):67-80. PubMed ID: 15604017
[TBL] [Abstract][Full Text] [Related]
3. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.
Erdmann M; Schuler-Thurner B
Methods Mol Biol; 2010; 595():149-63. PubMed ID: 19941110
[TBL] [Abstract][Full Text] [Related]
4. Generation of dendritic cell-based vaccines for cancer therapy.
Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
[TBL] [Abstract][Full Text] [Related]
5. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).
Javed A; Sato S; Sato T
Future Oncol; 2016 Mar; 12(6):751-62. PubMed ID: 26837440
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
Kvistborg P; Bechmann CM; Pedersen AW; Toh HC; Claesson MH; Zocca MB
Vaccine; 2009 Dec; 28(2):542-7. PubMed ID: 19837091
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells: limited potential in immunotherapy.
Soruri A; Zwirner J
Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
[TBL] [Abstract][Full Text] [Related]
8. Programming the next generation of dendritic cells.
Carroll RG; June CH
Mol Ther; 2007 May; 15(5):846-8. PubMed ID: 17446871
[No Abstract] [Full Text] [Related]
9. Current issues in delivering DCs for immunotherapy.
Barratt-Boyes SM; Figdor CG
Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986
[TBL] [Abstract][Full Text] [Related]
10. Monocyte Heterogeneity: Consequences for Monocyte-Derived Immune Cells.
Sprangers S; de Vries TJ; Everts V
J Immunol Res; 2016; 2016():1475435. PubMed ID: 27478854
[TBL] [Abstract][Full Text] [Related]
11. Personalized dendritic cell-based tumor immunotherapy.
Janikashvili N; Larmonier N; Katsanis E
Immunotherapy; 2010 Jan; 2(1):57-68. PubMed ID: 20161666
[TBL] [Abstract][Full Text] [Related]
12. Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs.
Rubio MT; Means TK; Chakraverty R; Shaffer J; Fudaba Y; Chittenden M; Luster AD; Sykes M
Int Immunol; 2005 Dec; 17(12):1561-72. PubMed ID: 16303787
[TBL] [Abstract][Full Text] [Related]
13. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
[TBL] [Abstract][Full Text] [Related]
14. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.
Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M
Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226
[TBL] [Abstract][Full Text] [Related]
15. New type of dendritic-cell-based cancer vaccine enters the clinic.
Hum Vaccin Immunother; 2012 Feb; 8(2):153-4. PubMed ID: 22745945
[No Abstract] [Full Text] [Related]
16. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K; Heirman C; Neyns B; Thielemans K
J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
[TBL] [Abstract][Full Text] [Related]
17. Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies.
Yi Q; Kwak LW
Clin Cancer Res; 2005 Feb; 11(3):966-7. PubMed ID: 15709160
[No Abstract] [Full Text] [Related]
18. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
[TBL] [Abstract][Full Text] [Related]
19. DC-based cancer vaccines: lessons from clinical trials.
Brody JD; Engleman EG
Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
[No Abstract] [Full Text] [Related]
20. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.
Hansen M; Hjortø GM; Donia M; Met Ö; Larsen NB; Andersen MH; thor Straten P; Svane IM
Vaccine; 2013 Jan; 31(4):639-46. PubMed ID: 23200882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
